Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Assets Average (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Assets Average for 5 consecutive years, with $495.3 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 14.92% to $495.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $495.3 million through Dec 2025, down 14.92% year-over-year, with the annual reading at $563.5 million for FY2025, 25.19% up from the prior year.
  • Assets Average for Q4 2025 was $495.3 million at 4D Molecular Therapeutics, up from $448.8 million in the prior quarter.
  • The five-year high for Assets Average was $625.0 million in Q2 2024, with the low at $247.8 million in Q3 2021.
  • Average Assets Average over 5 years is $392.1 million, with a median of $345.0 million recorded in 2022.
  • The sharpest move saw Assets Average skyrocketed 109.55% in 2024, then dropped 26.67% in 2025.
  • Over 5 years, Assets Average stood at $297.1 million in 2021, then dropped by 8.77% to $271.0 million in 2022, then grew by 29.43% to $350.8 million in 2023, then soared by 65.99% to $582.2 million in 2024, then dropped by 14.92% to $495.3 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $495.3 million, $448.8 million, and $494.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.